Vir Biotechnology, Inc. (VIR) stock
VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3021% below fair value
$9.96−2.16 (-17.82%)
Close on Nov 13, 2026Market cap $1.69BP/E –Yield –
Vir Biotechnology enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Vir Biotechnology's enterprise value was $1.69B on Nov 11, 2026, against $394.69M a year earlier. Over the last 5 years it ranged from -$835.55M to $4.54B, with a median of $394.69M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.69B | +397.2% |
| 2025 | Dec 31, 2025 | $340.47M | – |
| 2024 | Dec 31, 2024 | -$186.58M | – |
| 2023 | Dec 29, 2023 | -$346.95M | -135.9% |
| 2022 | Dec 30, 2022 | $966.92M | -78.7% |
| 2021 | Dec 31, 2021 | $4.54B | +76.3% |
| 2020 | Dec 31, 2020 | $2.57B | – |
| 2019 | Dec 31, 2019 | -$172.72M | – |
See a number that looks wrong?